NephrocalcinosisNCT07882355
Diagnostic Work-up of Nephrocalcinosis in Children
An observational study of Nephrocalcinosis, run by Assiut University.
Trial summary
This cross-sectional study aims to identify the underlying etiology of nephrocalcinosis and to evaluate the diagnostic work-up in infants and children presenting to Assiut University Children's Hospital. Read more about this study
- Who is it for?
- Ages Up to 18 years
- Conditions the study is for
- Nephrocalcinosis
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 20 Oct 2026to 1 Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Infants and children aged from birth to 18 years diagnosed with nephrocalcinosis by renal ultrasonography at Assiut University Children's Hospital.
Who may be able to join
- - Infants and children aged from birth to 18 years
- Diagnosed with nephrocalcinosis by renal ultrasonography
- Written informed consent from parent or legal guardian
Who cannot join
- Age above 18 years
- End-stage renal disease already on renal replacement therapy
- Refusal of informed consent by parents or caregivers
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Diagnostic Work-up of Infants and Children Presented With Nephrocalcinosis at Assiut University Hospital
This cross-sectional study aims to identify the underlying etiology of nephrocalcinosis and to evaluate the diagnostic work-up in infants and children presenting to Assiut University Children's Hospital.
Read the detailed description
Nephrocalcinosis is the deposition of calcium salts within the renal tubules and interstitium, most often detected by renal ultrasonography. In children, common causes include idiopathic hypercalciuria, hereditary tubulopathies, and prematurity-related factors.
This observational study will systematically evaluate the clinical, biochemical, urinary metabolic, radiological, and when indicated genetic findings in infants and children with nephrocalcinosis to determine the underlying etiology.
- Conditions
- Nephrocalcinosis
- Keywords
- Nephrocalcinosis, Children, Hypercalciuria, Renal ultrasonography, Assiut
- Medical subject headings
- Nephrocalcinosis, Hypercalciuria
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Children with Nephrocalcinosis | Infants and children with nephrocalcinosis undergoing systematic diagnostic work-up. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of children with identified etiology of nephrocalcinosis
Number of children in whom a specific underlying etiology of nephrocalcinosis is identified after complete diagnostic work-up.
Measured: Baseline
Secondary outcomes (4)
Number of children with hypercalciuria
Number of children with elevated spot urinary calcium/creatinine ratio.
Measured: Baseline
Number of children with history of prematurity
Number of children born preterm among those with nephrocalcinosis.
Measured: Baseline
Number of children with history of furosemide exposure
Number of children with documented prior exposure to furosemide.
Measured: Baseline
Serum calcium level
Mean serum calcium level in milligrams per deciliter.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2026
- Study start20 Oct 2026 (estimated)
- Primary completion20 Oct 2027 (estimated)
- Study completion1 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NephrocalcinosisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aya Ashraf Hanafy, Assiut University
- Investigators
- Ahlam B Ali, prof, Study chair, Pediatrics Department, Assiut University Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07882355
- Sponsor's protocol ID
- Nephrocalcinosis-Assiut-2026
- Status last verified
- Oct 2026
- First submitted
- 13 Oct 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnostic Work-up of Infants and Children Presented With Nephrocalcinosis at Assiut University Hospital
- ClinicalTrials.gov ID
- NCT07882355
- Acronym / sponsor ID
- Nephrocalcinosis-Assiut-2026
- Conditions
- Nephrocalcinosis
- Keywords
- Nephrocalcinosis, Children, Hypercalciuria, Renal ultrasonography, Assiut
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 20 Oct 2026 (estimated)
- Primary completion
- 20 Oct 2027 (estimated)
- Study completion
- 1 Mar 2028 (estimated)
- First posted
- 20 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This cross-sectional study aims to identify the underlying etiology of nephrocalcinosis and to evaluate the diagnostic work-up in infants and children presenting to Assiut University Children's Hospital.
Detailed description
Nephrocalcinosis is the deposition of calcium salts within the renal tubules and interstitium, most often detected by renal ultrasonography. In children, common causes include idiopathic hypercalciuria, hereditary tubulopathies, and prematurity-related factors.
This observational study will systematically evaluate the clinical, biochemical, urinary metabolic, radiological, and when indicated genetic findings in infants and children with nephrocalcinosis to determine the underlying etiology.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Children with Nephrocalcinosis | – | –Infants and children with nephrocalcinosis undergoing systematic diagnostic work-up. |
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Infants and children aged from birth to 18 years diagnosed with nephrocalcinosis by renal ultrasonography at Assiut University Children's Hospital.
Key inclusion criteria (3 listed)
- - Infants and children aged from birth to 18 years
- Diagnosed with nephrocalcinosis by renal ultrasonography
- Written informed consent from parent or legal guardian
Key exclusion criteria (3 listed)
- Age above 18 years
- End-stage renal disease already on renal replacement therapy
- Refusal of informed consent by parents or caregivers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of children with identified etiology of nephrocalcinosis
Time frame: Baseline
Number of children in whom a specific underlying etiology of nephrocalcinosis is identified after complete diagnostic work-up.
4 secondary outcomes
Number of children with hypercalciuria
Time frame: Baseline
Number of children with history of prematurity
Time frame: Baseline
Number of children with history of furosemide exposure
Time frame: Baseline
Serum calcium level
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Nephrocalcinosis
Enrolling by invitationObservational study
Epidemiology and Risk Factors of Nephrolithiasis and Nephrocalcinosis With Pediatric Onset
Nephrocalcinosis
RecruitingPhase 2
Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease
Not yet recruitingPhase 2/3
The GranStone Trial
Paraffinoma, Granuloma, Foreign-Body
Active, not recruitingPhase 3
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
Autosomal Dominant Hypocalcemia (ADH)
RecruitingObservational study
Effective Dosing of Burosumab in XLH
X-linked Hypophosphatemia (XLH)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ahlam B Ali, prof study chair
Pediatrics Department, Assiut University Hospitals
Questions about this trial
What is this clinical trial studying?
An observational study of Nephrocalcinosis, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aya A Hanafy, Resident (+20 10 26206491, ayaa99426@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of children with identified etiology of nephrocalcinosis (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.